54
53) Diederen PV, van Weelden H, Sanders CJ, Toonstra J, van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-9.
54) El-Mofty M, El-Darouty M, Salonas M et al. Narrowband UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study. Photodermatol Photoimmunol Photomed 2005; 21: 281-6.
55) Plettenberg H, Stege H, Megahed M et al. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 41: 47-50.
56) Zane C, Leali C, Air P, De Panfilis G, Pinton PC. “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.
57) Herr H, Cho HJ, Yu S. Burns caused by accidental overdose of photochemotherapy (PUVA). Burns 2007; 33: 372-5.
58) Laube S, George SA. Adverse effects with PUVA and UVB phototherapy. J Dermatolog Treat 2001; 12: 101-5.
59) Abdel Naser MB, Wollina U, El Okby M, El Shiemy S. Psoralen plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Clin Exp Dermatol 2004; 29: 380-2.
60) Hassab-El-Naby HM, Al-Ajmi HS, Al-Sabah HY, Kajeji MM. PUVA keratosis in vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 1013-4.
61) Kaya TI, Yazıcı AC, Türsen Ü, İkizoglu G. Idiopathic guttate hypomelanosis: idiopathic or ultraviolet induced? Photodermatol Photoimmunol Photomed 2005; 21: 270-1.
62) Park JH, Lee MH. Case of leukoderma punctata after topical PUVA treatment. Int J Dermatol 2004; 43: 138-9.
63) Norval M, Halliday GM. The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 2011; 87: 965-77.
64) Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 2759-64.
65) Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
66) Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-3.
67) Lindelöf B, Sigurgeirsson B, Tegner E et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12.



63. SAYFAYA BENZER SAYFALAR

Psoriasisli hastalarda lipid profili ve insülin direncinin değerlendirilmesi - Sayfa 73
86. Uyanik BS, Ari Z, Onur E, Gündüz K, Tanülkü S, Durkan K. Serum Lipids And Apolipoproteins In Patients With Psoriasis. Clin Chem Lab Med. 2002;40(1):65–8. 87. Lebwohl M, Ali S. Treatment Of Psoriasis. Part 1. Topical Therapy And Phototherapy. J Am Acad Dermatol 2001;45(4):487–98. 88. Van De Kerkhof PC, Vissers WH. The Topical Treatment Of Psoriasis. Skin Pharmacol Appl Skin Physiol 2003;16(2):6...
Dar bant UVB, UVA1 ve PUVA tedavilerinin melanositik nevusların dermatoskopik bulguları üzerine etkileri - Sayfa 83
ultraviolet A photochemotherapy for psoriasis. Br J Dermatol 2003; 148(6): 1194-204. 16. Snellman E, Klimenko T, Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol 2004; 84(2): 132-7. 17. Markham T, Rogers S, Collins P. Narrowband UV-B(TL-01) phototherapy vs oral 8-methoxypsoralen psoralen...

63. SAYFADAKI ANAHTAR KELIMELER

treat
therapy
narrowband
dermatol
study
ultraviolet


63. SAYFA ICERIGI

54
53) Diederen PV, van Weelden H, Sanders CJ, Toonstra J, van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-9.
54) El-Mofty M, El-Darouty M, Salonas M et al. Narrowband UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study. Photodermatol Photoimmunol Photomed 2005; 21: 281-6.
55) Plettenberg H, Stege H, Megahed M et al. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 41: 47-50.
56) Zane C, Leali C, Air P, De Panfilis G, Pinton PC. “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.
57) Herr H, Cho HJ, Yu S. Burns caused by accidental overdose of photochemotherapy (PUVA). Burns 2007; 33: 372-5.
58) Laube S, George SA. Adverse effects with PUVA and UVB phototherapy. J Dermatolog Treat 2001; 12: 101-5.
59) Abdel Naser MB, Wollina U, El Okby M, El Shiemy S. Psoralen plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Clin Exp Dermatol 2004; 29: 380-2.
60) Hassab-El-Naby HM, Al-Ajmi HS, Al-Sabah HY, Kajeji MM. PUVA keratosis in vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 1013-4.
61) Kaya TI, Yazıcı AC, Türsen Ü, İkizoglu G. Idiopathic guttate hypomelanosis: idiopathic or ultraviolet induced? Photodermatol Photoimmunol Photomed 2005; 21: 270-1.
62) Park JH, Lee MH. Case of leukoderma punctata after topical PUVA treatment. Int J Dermatol 2004; 43: 138-9.
63) Norval M, Halliday GM. The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 2011; 87: 965-77.
64) Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 2759-64.
65) Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
66) Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-3.
67) Lindelöf B, Sigurgeirsson B, Tegner E et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12.

İlgili Kaynaklar

single.php